bellerophon therapeutics stocktwits
Contacts At W2O Group: At LifeSci Advisors:Julie Normart Brian Ritchie(559) 974-3245(212) 915-2578jnormart@w2ogroup.combritchie@lifesciadvisors.com, Discover new investment ideas by accessing unbiased, in-depth investment research, NasdaqCM - NasdaqCM Real Time Price. For more information, please visit www.bellerophon.com. However, based on the absence of an efficacy signal and the availability of multiple vaccines, the Company will not be continuing the COViNOX trial. 6.05 +0.20 (3.42%)After hours: 7:43PM EDT, WARREN, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the fourth quarter and year ended December 31, 2020. BELLEROPHON THERAPEUTICS AKTIE und aktueller Aktienkurs. Bellerophon Therapeutics - Consensus Indicates Potential 294.3% Upside. We are focused on developing innovative therapies in the treatment of cardiopulmonary diseases.
The increase was primarily due to costs related to the Phase 3 COVID-19 and fILD trials. BLPH News: Bellerophon Therapeutics EPS beats by $0.17: 03/11/2021 09:18:45 AM: BLPH News: Current Report Filing (8-k) 03/11/2021 08:36:24 AM: BLPH News: Current Report Filing (8-k) 01/11/2021 08:02:23 AM: BLPH News: Amended Statement of Ownership (sc 13g/a) 01/05/2021 01:52:57 PM: BLPH News: Current Report Filing (8-k) 12/01/2020 08:32:16 AM: Post New Msg; Follow Board; My … This browser is no longer supported at MarketWatch. For more information, please visit www.bellerophon.com. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Bellerophon to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference. Stockhouse.com use cookies on this site. PH-Sarc is an unmet medical need with a median survival of approximately five years after diagnosis. General and administrative expenses for the fourth quarter ended December 31, 2020 were $2.0 million, compared to $1.5 million in the prior year period. Featured Post From StockTwits About BLPH Wednesday … Our mission is to develop well-studied molecules deployed through innovative delivery systems to treat diseases with significant unmet clinical need. By continuing to use our service, you agree to our use of cookies. 2. Bellerophon Therapeutics Aktie im Überblick: Realtimekurs, Chart, Fundamentaldaten, sowie aktuelle Nachrichten und Meinungen. The company was founded in 2009 and is headquartered in Warren, NJ. By using this site you agree to the
Bellerophon Provides Clinical Program Update and Reports Third Quarter 2020 Financial … Bellerophon Therapeutics, Inc. (BLPH) Today's Latest Price: $7.21 USD. This ist not a casino! Research and development expenses for the fourth quarter ended December 31, 2020 were $6.1 million, compared to $2.8 million in the prior year period. Net loss for the three months ended December 31, 2020 included income of $0.4 million due to a change in fair value of the Company’s common stock warrant liability, as compared to $0.2 million in the fourth quarter of 2019. Bellerophon Therapeutics Aktie im Überblick: Realtimekurs, Chart, Fundamentaldaten, sowie aktuelle Nachrichten und Meinungen.
Forward-looking StatementsAny statements in this press release about Bellerophon’s future expectations, plans and prospects, including statements about the clinical development of its product candidates, regulatory actions with respect to the Company’s clinical trials and expectations regarding the sufficiency of the Company’s cash balance to fund clinical trials, operating expenses and capital expenditures, and other statements containing the words “anticipate,” “believe,” “continue,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Privacy Notice, and
The safety and efficacy study is assessing the acute hemodynamic benefit of INOpulse via right heart catheterization. Company Name: Bellerophon Therapeutics Inc, Stock Symbol: BLPH, Industry: Biotechs, Total Posts: 675, Last Post: 11/23/2020 8:49:45 AM
5) Bellerophon Therapeutics Added to Russell 3000® and Microcap 6) Preliminary data demonstrated that at day 14 from treatment initiation, recovery rate was 73.0% and mortality rate was 6.3% So guys why are you crying? 128,888 Its product pipeline include PH-ILD, PH-COPD, and PH-Sarc. Bellerophon Therapeutics started at buy with $3 stock price target at Maxim Group Jan. 24, 2019 at 7:30 a.m. Corporate Update: In 2020, a patent covering the shape of the nitric oxide pulse and valve configuration of our proprietary INOpulse drug delivery device was issued in the U.S. with an expiry date of June 2039. Create a list of the investments you want to track. Very extensive DD and updated Price Targets to all swings will be posted then too. All quotes are in local exchange time. Three equities research analysts have rated the stock with a strong buy rating. The company belongs in the Biotechnology industry, Healthcare sector and employs 17 … A high-level overview of Bellerophon Therapeutics, Inc. (BLPH) stock. Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Nachrichten zur Aktie Bellerophon Therapeutics Inc Registered Shs | A2PZZR | BLPH | US0787713009 ET by Tomi Kilgore Bellerophon … Prior to joining Bellerophon, Dr. Parsley most recently served as Acting Chief Medical Officer for Respira Therapeutics, in the development of inhaled vardenafil powder for symptomatic use in pulmonary arterial hypertension (PAH). Similar to PH associated with fILD, there are currently no approved therapies to treat PH-Sarc. © 2021 Verizon Media. The increase was primarily due to IP, consulting, and labor costs. Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Cookie Notice (). Get the latest Bellerophon Therapeutics, Inc. BLPH detailed stock quotes, stock … Insider Chart Past 6 Months . BLPH Symbol Info by TradingView. Overall POWR Rating . Wie schätzen Analysten die Lage ein? Bellerophon Therapeutics began the day with a market capitalization of around $15.5 million with approximately 4.58 million shares outstanding and a short interest of about 2.1%. For email alerts: Sign in - or - Join. General and administrative expenses for the year ended December 31, 2020 were $8.4 million, compared to $6.4 million for the year ended December 31, 2019. Acute treatment with INOpulse showed benefit in multiple cardiopulmonary parameters, including pulmonary vascular resistance, which improved by 21%, and mean pulmonary arterial pressure, which improved by 12%. “In December 2020, we announced that the first patient had been enrolled in our pivotal Phase 3 REBUILD study for fibrotic interstitial lung disease (fILD) patients at risk of associated pulmonary hypertension. The issued patent builds upon the Company’s portfolio of over 100 issued and pending patent applications and the Orphan Drug Designation for nitric oxide for the treatment of idiopathic pulmonary fibrosis in the U.S., which can provide up to 7 years of exclusivity if the product is approved.In November 2020, the Company presented at the H.C. Wainwright 6th Annual Israel Conference.In January 2021, Bellerophon presented at the H.C. Wainwright Virtual BioConnect 2021 Conference. View Bellerophon Therapeutics, Inc. BLPH investment & stock information. Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Cookies are used to offer you a better browsing experience and to analyze our traffic. All rights reserved. The increase was primarily due to IP, consulting, and labor costs. Share your opinion and gain insight from other stock traders and investors. Morningstar thinks these companies are well positioned to benefit from one of five key trends during the next decade. ZOM 2.13 0.14 (5.97%). ContactsLifeSci Advisors:Brian Ritchie (212) 915-2578britchie@lifesciadvisors.com BELLEROPHON THERAPEUTICS, INC. Consolidated Balance Sheets (Amounts in thousands, except share and per share data) December 31, 2020 December 31, 2019Assets Current assets: Cash and cash equivalents $47,557 $9,874 Restricted cash 103 103 Prepaid expenses and other current assets 420 405 Total current assets 48,080 10,382 Restricted cash, non-current 300 300 Right of use assets, net 1,504 2,110 Property and equipment, net 169 316 Other non-current assets 186 — Total assets $50,239 $13,108 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $3,725 $3,106 Accrued research and development 3,699 2,117 Accrued expenses 2,305 1,703 Current portion of operating lease liabilities 704 658 Total current liabilities 10,433 7,584 Long term operating lease liabilities 956 1,659 Common stock warrant liability 601 274 Total liabilities 11,990 9,517 Commitments and contingencies Stockholders' equity: Common stock, $0.01 par value per share; 200,000,000 shares authorized and9,491,111 and 4,580,127 shares issued and outstanding at December 31, 2020and December 31, 2019, respectively 95 46 Preferred stock, $0.01 par value per share; 5,000,000 shares authorized, zeroshares issued and outstanding at December 31, 2020 and December 31, 2019 — — Additional paid-in capital 252,645 193,308 Accumulated deficit (214,491) (189,763)Total stockholders' equity 38,249 3,591 Total liabilities and stockholders' equity $50,239 $13,108 BELLEROPHON THERAPEUTICS, INC. Consolidated Statements of Operations (Amounts in thousands, except share and per share data) Year Ended December 31, 2020 2019 Operating expenses: Research and development $17,890 $11,032 General and administrative 8,386 6,441 Total operating expenses 26,276 17,473 Loss from operations (26,276) (17,473) Change in fair value of common stock warrant liability (327) 2,682 Warrant amendment charge — (674) Interest income and financing expenses, net (250) 397 Pre-tax loss (26,853) (15,068) Income tax benefit 2,125 1,801 Net (loss) income $(24,728) $(13,267) Weighted average shares outstanding: Basic 7,797,130 4,503,375 Diluted 7,797,130 4,503,375 Net (loss) income per share: Basic $(3.17) $(2.95) Diluted $(3.17) $(2.95). Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. INK Edge Outlook. Find the latest Bellerophon Therapeutics, Inc. (BLPH) stock discussion in Yahoo Finance's forum. Bellerophon Therapeutics, Inc. Common Stock (BLPH) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets. Its product pipeline include PH-ILD, PH-COPD, and PH-Sarc. Bellerophon Therapeutics, Inc. focuses on developing products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. If approved, INOpulse would become the first therapy to treat a broad fILD population that includes patients at low-, intermediate- and high-risk of pulmonary hypertension.The Phase 3 program builds on positive top-line results from the Company’s previously reported Phase 2 studies for INOpulse for the treatment of fILD. Technical Chart . Log in to see them here or sign up to get started. 2020 Year End Financial Results:For the year ended December 31, 2020, the Company reported a net loss of $24.7 million, or $(3.17) per share, compared to net loss of $13.3 million, or $(2.95) per share, in the year ended December 31, 2019. The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery system. The firm develops innovative products combining novel drugs and devices to treat cardiopulmonary diseases. Healthcare . Bellerophon Therapeutics Announces Closing of $43.7 Million Public Offering of Common Stock and Concurrent Registered Direct Offering and Full Exercise of Option to Purchase Additional Shares finance.yahoo.com - May 22 at 2:53 PM: Bellerophon down 13% after pricing stock offering seekingalpha.com - May 19 at 9:45 AM : Bellerophon Therapeutics Announces Pricing of Public … Featured Post From StockTwits About BLPH Wednesday will add plenty more tickers. Bellerophon Therapeutics (BLPH) Reports Q3 Loss, Lags Revenue Estimates: Nov 5: Bellerophon Therapeutics EPS misses by $0.01: Nov 5 : Bellerophon Provides Clinical Program Update and Reports Third Quarter 2020 Financial Results: Nov 1: The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings: Oct 29: Bellerophon to Present … There are currently no items in this Watchlist. Die Aktie der Bellerophon Therapeutics wurde in den vergangenen zwölf Monaten von Analysten aus Research-Abteilungen 0.17 (2.41%) Updated Jan 8 4:00pm. A Amended Filing. The company engages in the development of INOpulse that is in Phase 2 clinical trial for … Cleaner Indoor Air Is
Time to Start Paying Down Debt, Uncle Sam, 2 Stocks With Earnings Growth Beyond 2021, Bond Vigilantes Are Back, but Unlikely to Cause a New Black Monday for Stocks, Global Emphasis on
Add BLPH to Watchlist Sign Up. Net loss for the year ended December 31, 2020 included an expense of $0.3 million due to a change in fair value of the Company’s common stock warrant liability, as compared to an income of $2.7 million in the year ended December 31, 2019. In addition, we expect top-line results from our Phase 2 dose escalation study of INOpulse in sarcoidosis (PH-Sarc) this year.” “Our balance sheet continues to be strong and provides us with the resources to support our ongoing clinical programs in fILD and PH-Sarc,” concluded Mr. Tenenbaum. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. The increase was primarily due to costs related to the Phase 3 COVID-19 and fILD trials. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release. Stockhouse.com use cookies on this site. By clicking this link, you'll be leaving the Bellerophon Therapeutics website and opening a site not sponsored by Bellerophon Therapeutics. BLPH 6.82 0.11 (1.59%). Upon completion of the protocol defined monitoring period, the safety and efficacy analysis of the full 191 patients was reviewed by the DMC, and the DMC determined that there were no safety concerns attributed to INOpulse. Intraday Data provided by FACTSET and subject to terms of use.
GlobeNewswire November 23, 2020. Bellerophon to Present at the H.C. Wainwright 6th Annual Israel Conference. COVID-19 (Coronavirus) COViNOX Phase 3 Study: The randomized, placebo-controlled COViNOX study evaluated the efficacy and safety of the investigational INOpulse therapy in patients diagnosed with COVID-19 who require supplemental oxygen. About BellerophonBellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary and infectious diseases. Description: Bellerophon Therapeutics Inc is a clinical-stage biotherapeutics company. Find the latest Bellerophon Therapeutics, Inc. (BLPH) stock quote, history, news and other vital information to help you with your stock trading and investing. Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) was in 4 hedge funds' portfolios at the end of the first quarter of 2020. Subscriber Agreement & Terms of Use,
Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: risks and uncertainties relating to INOpulse®, the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary or interim results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals, the FDA’s substantial discretion in the approval process, availability of funding sufficient for our foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K and in subsequent filings with the Securities and Exchange Commission. It develops products under its INOpulse platform, which is an extension of the technology that is used in hospitals to deliver continuous-flow inhaled nitric oxide. Filings by filing date . About BellerophonBellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. For the best MarketWatch.com experience, please update to a modern browser. Previously, he was Medical Monitor and consulting Chief Medical Officer for Liquidia Technologies in the development of inhaled treprostinil for PAH. Chronic treatment with INOpulse at a dose of iNO45 assessed over four months showed an average improvement in MVPA of 20% as compared to placebo. Visit a quote page and your recently viewed tickers will be displayed here. Currency in USD, Trade prices are not sourced from all markets, 24 Stocks Positioned For Growth This Decade. Bellerophon Therapeutics Inc. (NASDAQ: BLPH) stock closed at 7.1 per share at the end of the most recent trading day (a -1.25 % change compared to the prior day closing price) with a volume of 28.59K shares and market capitalization of 67.44M.Is a component of indices and it is traded on NASDAQ exchange. Bellerophon Therapeutics started at buy with $3 stock price target at Maxim Group Jan. 24, 2019 at 7:30 a.m. Bellerophon Therapeutics, Inc. Common Stock (BLPH) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Bellerophon Therapeutics NASDAQ Updated Mar 16, 2021 9:27 PM. Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Industry Rank: Ranked of 523 in Biotech. See all "A" rated Strong Buy stocks. The company belongs in the Biotechnology industry, Healthcare sector and employs 17 … Shares of Bellerophon Therapeutics Inc (NASDAQ:BLPH) have earned an average broker rating score of 1.00 (Strong Buy) from the three analysts that cover the stock, Zacks Investment Research reports. Trade Date Insider Title Buy/Sell #Shares Price Value Option; 2020-09-10 FARES Wassim: Chief Medical Officer: Buy: 4,000: $10.18: $40,708: No: 2020-06-08 Wang Theodore T: 10%-Owner, Director: Buy: 7,586: $12.77: $96,896: No: … Sign Up to See Ratings...FREE! Bellerophon Therapeutics, Inc. focuses on developing products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. “Bellerophon continues to make significant progress in advancing its INOpulse® inhaled nitric oxide therapy in multiple indications,” said Fabian Tenenbaum, Chief Executive Officer of Bellerophon. Copyright © 2021 MarketWatch, Inc. All rights reserved. Balance SheetAs of December 31, 2020, the Company had cash and cash equivalents of $47.6 million, compared to cash and cash equivalents of $9.9 million at December 31, 2019. Healthcare. In addition, any forward-looking statements included in this press release represent Bellerophon’s views only as of the date of this release and should not be relied upon as representing the Company’s views as of any subsequent date. 2 Be patient or sell! Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The primary endpoint is change in moderate to vigorous physical activity (MVPA). Show only public market trades. Something went wrong while loading Watchlist. Intraday data delayed at least 15 minutes or per exchange requirements. Based on the recommendation of the DMC, the COViNOX study was placed on clinical hold. The company was founded in 2009 and is headquartered in Warren, NJ. I expect constructive discussions! Bellerophon Therapeutics: A Promising Solution To America's Ventilator Shortage During The COVID-19 Pandemic Apr. Bellerophon Therapeutics, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Research and development expenses for the year ended December 31, 2020 were $17.9 million, compared to $11.0 million in the year ended December 31, 2019.
Bellerophon Therapeutics LLC, a clinical-stage therapeutics company, focuses on the development of various products for the treatment of cardiopulmonary and cardiac diseases. More About Us . For the latest outlook, get the company report . The presentation will be available on-demand beginning on Tuesday, March 9, 2021, in the Investors section on the Company’s website at www.bellerophon.com. Three Ways To Make Better Decisions in Markets; Valuations never mattered: You are trading the crowd; You might consider price ranges over price targets
Filings by transaction date . Pulmonary Hypertension-Sarcoidosis (PH-Sarc) Phase 2 Clinical Study: Bellerophon is continuing enrollment in a Phase 2 dose escalation study in PH-Sarc and anticipates the availability of top-line data during 2021. WARREN, N.J., March 02, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference, being held virtually March 9-10, 2021. The improvements in MVPA were supported by benefits in overall activity, as well as two patient reported questionnaires, the University of California, San Diego Shortness of Breath Questionnaire and the St. George’s Respiratory Questionnaire. GlobeNewswire November 11, 2020. Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Virtual BioConnect 2021 Conference, being held January 11-14, 2021. Fourth Quarter Financial Results:For the fourth quarter ended December 31, 2020, the Company reported a net loss of $8.0 million, or $(0.84) per share, compared to a net loss of $4.1 million, or $(0.89) per share, in the fourth quarter ended December 31, 2019.
Get the latest Bellerophon Therapeutics, Inc. BLPH detailed … Bellerophon Therapeutics Inc (OQ:BLPH) * Real-time data source: IEX. Cloudy as of December 01, 2020. Zomedica Pharmaceuticals Corp NYSEArca Updated Mar 17, 2021 3:21 PM. Bellerophon Therapeutics Announces Results of Interim Analysis of Phase 3 COViNOX Study of INOpulse® for the Treatment of COVID-19. Bellerophon Therapeutics, Inc. focuses on developing products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. Post-Market 0.07 (1.03%) The company was founded in … Clinical Program Highlights:fILD REBUILD Phase 3 Study: In December, Bellerophon announced that the first patient had been enrolled in its Phase 3 REBUILD registrational study of INOpulse for the treatment of fILD. ET by Tomi Kilgore Bellerophon shares surge … Historical and current end-of-day data provided by FACTSET. Bellerophon to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference. Have Watchlists? Bellerophon Therapeutics is a clinical-stage biotherapeutics company. View Bellerophon Therapeutics, Inc. BLPH investment & stock information. The REBUILD study will enroll 300 fILD patients who will be treated with either INOpulse at a dose of iNO45 or placebo. Bellerophon Therapeutics Inc. (NASDAQ: BLPH) stock closed at 7.17 per share at the end of the most recent trading day (a 3.46 % change compared to the prior day closing price) with a volume of 45.43K shares and market capitalization of 68.10M.Is a component of indices and it is traded on NASDAQ exchange. Cool Trend for Trane, Bellerophon Therapeutics started at buy with $3 stock price target at Maxim Group, Bellerophon Therapeutics shares jump 28% premarket, Bellerophon Therapeutics announces positive results in trial of pulmonary hypertension treatment, Bellerophon Therapeutics' stock plunges 60% after disappointing drug trial results, Bellerophon stock is up 35% on hypertension trial data, Bellerophon shares surge 20% premarket on positive results in trial of COPD treatment, Bellerophon shares skyrocket on high blood pressure drug study, H.C. Wainwright Reaffirms Their Buy Rating on Bellerophon (BLPH), Bellerophon (BLPH) Gets a Buy Rating from Maxim Group, Bellerophon (BLPH) Gets a Buy Rating from H.C. Wainwright, Bellerophon Therapeutics (BLPH) Reports Q3 Loss, Lags Revenue Estimates, Biotech Stock Roundup: INCY's Solid Q4 Results, EPZM & SGEN's Pipeline Updates. Bellerophon Therapeutics does control the content of this site and is not responsible or liable for the accuracy of the content presented within any external site. In November 2020, the Company announced the results of a pre-specified interim analysis conducted by an independent Data Monitoring Committee (DMC). POWR Components: Trade Grade Buy & Hold Grade Peer Grade Industry Rank. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. News . Bellerophon Therapeutics Inc. stock and Biotechnology market discussion, news, and analysis from Canada's largest community of active investors. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. Biz Brief . All the the negativity is senseless.. please sell! Bellerophon Therapeutics Inc. stock and Biotechnology market discussion, news, and analysis from Canada's largest community of active investors. Cookies are used to offer you a better browsing experience and to analyze our traffic. Its product pipeline include PH-ILD, PH-COPD, and PH-Sarc. The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery system. By continuing to use our service, you agree to our use of cookies.